Stay updated on Pembrolizumab for Genomic Instability Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Genomic Instability Clinical Trial page.

Latest updates to the Pembrolizumab for Genomic Instability Clinical Trial page
- Check7 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. This appears to be a minor front-end update with no visible changes to the study details or related content.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedRevision: v3.4.3 was added, replacing the previous Revision: v3.4.2.SummaryDifference0.1%

- Check29 days agoNo Change Detected
- Check44 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2. Core study details, eligibility criteria, and contact information appear unchanged.SummaryDifference0.1%

- Check51 days agoChange DetectedA minor revision update from v3.4.0 to v3.4.1 is shown; no other content changes are observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check58 days agoChange DetectedThe page now includes a Show glossary option and new QC metadata labels, including Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0, replacing the prior Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

- Check73 days agoChange DetectedThe page revision updated from v3.3.3 to v3.3.4. No study data, eligibility criteria, or locations were modified. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for Genomic Instability Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Genomic Instability Clinical Trial page.